Assessment of Safety , Clinical Efficacy With QLETLI in Non-infectious Uveitis (UV)
Status:
Not yet recruiting
Trial end date:
2023-05-30
Target enrollment:
Participant gender:
Summary
This is a multicenter, prospective, post-marketing clinical study with a total of 60 uveitis
(UV) subjects planned to be enrolled.
Screening period (-2~0 weeks) ,Treatment period (1-22 weeks), Follow-up period, At the same
time, plasma concentration will be determined